

	AVASTIN	LUCENTIS	EYLEA	Brolucizumab
Baseline Q4 2013	64%	36%	0%	
Q2 2014	57%	36%	7%	
Q3	49%	32%	19%	
Q4	51%	30%	19%	
Q1 2015	44%	23%	33%	
Q2	42%	22%	36%	
Q3	40%	21%	39%	
Q4	41%	20%	39%	
Q1 2016	46%	15%	39%	
Q2	43%	16%	41%	
Q3	43%	20%	38%	
Q4	45%	17%	38%	
Q1 2017	43%	20%	37%	
Q2	46%	14%	40%	
Q3	42%	17%	41%	
Q4	43%	17%	40%	
Q1 2018	43%	19%	38%	
Q2	42%	18%	40%	
Q3	41%	21%	38%	
Q4	41%	18%	41%	
Q1 2019	36%	23%	41%	
Q2	38%	22%	40%	
Q3	35%	23%	42%	
Q4	37%	16%	47%	
Q1 2020	41%	16%	41%	2%
Q2	40%	19%	39%	2%
Q3	40%	15%	42%	3%
Q4	40%	15%	43%	2%
Q2 2021	38%	15%	44%	3%

Mylan v. Regeneron  
 IPR2021-00881  
 U.S. Pat. 9,254,338  
 Exhibit 2281